InspireMD, Inc. (NYSEMKT:NSPR) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.
InspireMD, Inc. (the Company) intends, from time to time, to
present and/or distribute to the investment community and utilize
at various industry and other conferences a slide presentation,
which is attached hereto as Exhibit 99.1. The Company undertakes
no obligation to update, supplement or amend the materials
attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the
Securities Act of 1933, as amended, except as shall be expressly
set forth by reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description | |
| 99.1 | Slide Presentation of InspireMD, Inc. dated March 2017 |
About InspireMD, Inc. (NYSEMKT:NSPR)
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. InspireMD, Inc. (NYSEMKT:NSPR) Recent Trading Information
InspireMD, Inc. (NYSEMKT:NSPR) closed its last trading session down -0.030 at 0.940 with 450,961 shares trading hands.
